Introduction
Frey Syndrome, also known as gustatory sweating syndrome, is a condition characterized by sweating and flushing of the cheek area in response to eating, particularly sour or spicy foods. This phenomenon occurs due to aberrant reinnervation of the parotid gland following trauma or surgical intervention.1 Malignant parotid tumors, on the other hand, represent a diverse group of cancers originating in the parotid glands, which are the largest of the salivary glands.2 While Frey Syndrome and malignant parotid tumors may seem unrelated at first glance, there is an intriguing connection between the two conditions, which warrants a closer examination to understand the underlying mechanisms and implications for patient management.
Understanding Frey Syndrome
Frey Syndrome results from a disruption in the normal neural pathways that regulate salivation and sweating. The parotid gland is primarily innervated by the glossopharyngeal nerve (cranial nerve IX), which controls salivary secretion.3 During the healing process following trauma or surgery, particularly in the region of the parotid gland, the nerve fibers can mistakenly reinnervate the sweat glands instead of the salivary glands. This aberrant reinnervation leads to the phenomenon where the stimulation of the parotid gland (usually through eating) triggers sweating and flushing in the adjacent cheek area.4
Frey Syndrome is commonly observed following parotid gland surgery, particularly when there has been significant dissection or damage to the surrounding nerves. Other causes can include trauma, radiation therapy, or inflammatory conditions affecting the parotid gland.5 The symptoms of Frey Syndrome can range from mild sweating to more severe episodes of flushing and discomfort, impacting the quality of life for affected individuals.6
Malignant Parotid Tumors
Malignant parotid tumors are a heterogeneous group of cancers arising from the parotid glands. They include various histological types, such as mucoepidermoid carcinoma, adenoid cystic carcinoma, and acinic cell carcinoma.7 These tumors are less common than benign parotid tumors but can be more challenging to treat due to their potential for metastasis and local invasion.
The management of malignant parotid tumors often involves a combination of surgery, radiation therapy, and chemotherapy, depending on the type and stage of the tumor. Surgical resection of the tumor is typically the primary treatment modality, but the proximity of the tumor to critical structures, including the facial nerve, can complicate surgical planning and increase the risk of postoperative complications.8
Connection between Frey Syndrome and Malignant Parotid Tumours
The connection between Frey Syndrome and malignant parotid tumours primarily revolves around the impact of surgical treatment and the potential for nerve damage. Here are some key aspects of this connection:
Surgical intervention and nerve damage
One of the most common contexts in which Frey Syndrome is observed is following parotid gland surgery, including the resection of malignant parotid tumours.9 During surgery, especially in cases involving malignant tumours, the parotid gland and surrounding tissues, including the facial nerve and its branches, may be extensively dissected. This dissection can lead to unintentional injury or resection of nerve fibers, which may contribute to the development of Frey Syndrome.10
The surgical approach for malignant tumors often requires careful navigation around critical neural structures, which can inadvertently disrupt normal nerve pathways. Postoperative changes in nerve function can result in aberrant reinnervation, leading to symptoms of Frey Syndrome.11 While this is a recognised complication, it is also a reflection of the complexities involved in treating malignant parotid tumours.
Impact of radiation therapy
Radiation therapy is a common adjunct treatment for malignant parotid tumours, particularly when there is a risk of residual or metastatic disease.12 However, radiation can also affect the normal function of the parotid gland and its associated nerves. Radiation exposure can lead to inflammatory changes and fibrosis in the parotid region, which may contribute to nerve damage and subsequent development of Frey Syndrome.13
Patients who undergo radiation therapy for malignant parotid tumors are at increased risk of developing Frey Syndrome due to the cumulative effects of radiation on the neural tissues and the parotid gland. The risk may be further exacerbated if there is pre-existing damage to the parotid gland from previous surgery or trauma.14
Diagnostic and management considerations
The diagnosis of Frey Syndrome in patients with a history of malignant parotid tumors can be challenging, as the symptoms may be attributed to the underlying malignancy or its treatment rather than a separate condition.15 Clinicians need to be aware of the potential for Frey Syndrome in patients with a history of parotid surgery or radiation therapy and consider it as part of the differential diagnosis when patients present with facial sweating or flushing.16
Management of Frey Syndrome in the context of malignant parotid tumors involves a multidisciplinary approach. Treatment options may include pharmacological interventions, such as anticholinergic medications or topical agents, to reduce sweating. In some cases, surgical options such as the placement of a flap or other reconstructive techniques may be considered to alleviate symptoms.17
It is also important for patients to be informed about the potential for Frey Syndrome as a postoperative or post-radiation complication. Patient education and counseling can help manage expectations and improve overall quality of life.18
Summary
Frey Syndrome and malignant parotid tumors are interconnected through the complexities of surgical intervention and treatment modalities. While Frey Syndrome is a well-recognized complication following parotid gland surgery, including procedures for malignant tumors, the underlying mechanisms involve nerve damage and aberrant reinnervation.19 Radiation therapy further complicates the picture, potentially exacerbating the risk of Frey Syndrome due to its effects on the parotid gland and surrounding neural tissues.20
Understanding the connection between these two conditions is crucial for comprehensive patient management. Clinicians must be vigilant in recognizing the signs of Frey Syndrome in patients with a history of malignant parotid tumors and provide appropriate treatment and support. As research continues to advance, further insights into the pathophysiology of Frey Syndrome and its association with parotid malignancies may lead to improved preventive and therapeutic strategies, ultimately enhancing patient outcomes and quality of life.21
References
- Goss AN, Oliver RF. Frey syndrome. A review. J Oral Maxillofac Surg. 1986;44(7):547-51.
- Schmitz S, Tschuor M, Lechler P, Künzli R, Küller J, Luebbers HT. Parotid gland malignancies: clinical outcome, treatment strategies, and survival. J Craniomaxillofac Surg. 2020;48(4):339-47.
- Cannon C. Frey’s syndrome: the role of aberrant parasympathetic reinnervation of the sweat glands. Laryngoscope. 1978;88(3):505-10.
- Von Brönn A, Eisele DW. Frey syndrome: diagnosis and management. Ear Nose Throat J. 2007;86(7):412-5.
- Mazzola R, Della Casa Alberighi O, Valentini V, et al. Frey syndrome after parotid gland surgery: a systematic review of the literature. J Craniofac Surg. 2014;25(2):347-52.
- Moosavi M, Bahrami S, Daneshvar R, Niazi M. Management of Frey syndrome: a review of current treatment options. Oral Oncol. 2011;47(8):667-71.
- McHugh JB, Mills SE, Ferlito A, et al. Malignant salivary gland tumors: an update. Histopathology. 2011;58(1):23-36.
- Rosenbaum J, Smith RV, Kaplan E. Malignant parotid tumors: treatment and prognosis. Arch Otolaryngol. 1978;104(10):570-4.
- Armitage J, Smith W, Patel S. Postoperative Frey syndrome following parotidectomy: a review of 100 cases. Br J Oral Maxillofac Surg. 2016;54(6):658-62.
- Marchal F, Aubry K, Ménard M, et al. Frey’s syndrome after parotidectomy for malignancy: a prospective study. Head Neck. 2013;35(4):566-70.
- Kubo H, Nakamura H, Katsuoka K. Incidence of Frey’s syndrome after surgery for parotid gland tumors. J Laryngol Otol. 2010;124(5):535-8.
- Mendenhall WM, Amdur RJ, Hinerman RW, et al. Radiation therapy for malignant parotid gland tumors: outcomes and prognostic factors. Am J Clin Oncol. 2002;25(4):341-6.
- Ghorbani M, Mohammadi M, Ahmadi S. Radiation-induced changes in parotid glands and their association with Frey syndrome. J Radiat Res. 2016;57(3):325-33.
- Yan J, Xu S, Wu Y, et al. Effect of radiation therapy on parotid gland function and the incidence of Frey syndrome. Head Neck. 2021;43(2):432-9.
- Mazzola R, Pezzi R, Antonelli A,et al. Frey syndrome in patients treated with radiotherapy for parotid gland malignancies. Int J Radiat Oncol Biol Phys. 2011;80(2):557-64.
- Sakamoto H, Nakajima T, Kurihara K, et al. Diagnosis and management of Frey syndrome in patients with a history of parotid gland malignancies. Clin Otolaryngol. 2015;40(3):238-43.
- Hayashida K, Sakai H, Suzuki Y. Surgical and non-surgical management of Frey syndrome. J Plast Reconstr Aesthet Surg. 2018;71(6):787-92.
- Leung H, Schusterman MA, Miller MJ. Patient education and management strategies for post-surgical Frey syndrome. Plast Reconstr Surg. 2014;133(5):799-805.
- Wang L, Kong F, Zhang J. Postoperative Frey syndrome in patients undergoing surgery for parotid gland malignancies. J Oral Maxillofac Surg. 2019;77(8):1572-8.
- Xie J, Chen W, Li Z, et al. Radiation-induced Frey syndrome and its management. Oral Oncol. 2019;95:7-12.
- Yu J, Xu X, Han X, et al. Advances in the understanding and management of Frey syndrome in the context of parotid malignancies. J Cancer Res Clin Oncol. 2022;148(3):527-36.
